Financial Arrangements

This paper and panel discussion are part of the symposium entitled, Mining the Deep Seabed: A Range of Perspectives. The issues that are dealt with in the negotiating group fall into three groups: what kinds of payments would the contractor make to the Authority, when the payments would be made, and how much would be paid

Mining the Deep Seabed: A Range of Perspectives

Introduction to the symposium entitled: Mining the Deep Seabed: A Range of Perspectives. The introduction is written by Roger H. Hull, who introduces the panel, people in attendance, and core issues involving the system of exploration and exploitation for the the deep seabed resource policy, financial arrangements, and the structure of the Authority, which all parties agree will play a major role in the development of the deep seabed

Novel Therapies of Hepatitis B and D

Hepatitis B virus (HBV) infection is a global public health issue and is a major cause of cirrhosis and hepatocellular carcinoma (HCC). Hepatitis D virus (HDV) requires the hepatitis B surface antigen (HBsAg) to replicate. The eradication of HBV, therefore, can also cure HDV. The current therapies for chronic hepatitis B and D are suboptimal and cannot definitely cure the viruses. In order to achieve functional or complete cure of these infections, novel therapeutic agents that target the various sites of the viral replicative cycle are necessary. Furthermore, novel immunomodulatory agents are also essential to achieve viral clearance. Many of these new promising compounds such as entry inhibitors, covalently closed circular DNA (cccDNA) inhibitors, small interfering RNAs (siRNAs), capsid assembly modulators and nucleic acid polymers are in various stages of clinical developments. In this review article, we provided a comprehensive overview of the structure and lifecycle of HBV, the limitations of the current therapies and a summary of the novel therapeutic agents for both HDV and HBV infection